Trial Profile
Retrospective study of sacubitril/valsartan on left ventricular reverse remodeling heart failure associated with reduced ejection fraction
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Mar 2020
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure
- Focus Adverse reactions; Therapeutic Use
- 06 Mar 2020 patient segment primary and secondary prevention have been assumed from result: 3458266.
- 07 Nov 2019 Results published in the Acta Cardiologica
- 25 Nov 2018 Results assessing impact of sacubitril/valsartan on functional status and exercise capacity, published in the Acta Cardiologica.